This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.
Patients meeting inclusion/exclusion criteria will be approached for study consent based on
the time of hospital admission and the availability of an blood type compatible product.
300mL plasma units of COVID-19 convalescent patients will be utilized for transfusion. During
a period of 14 days, the patient will be eligible to receive up to 10 units of plasma, to be
completed with 4 hours as per institutional transfusion standard operating procedures.
Transfusion by apheresis (plasma exchange) may be employed to reduce the risk of volume
overload. The number of units to be used will be determined by the study team based on
protocol inclusion and exclusion criteria, and clinical evaluation of the patient's severity
and response.
Subjects will be followed for at least 60 days or up to 3 months following initial
transfusion for adverse event monitoring and data collection.
Biological: COVID 19 Convalescent Plasma
COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
Inclusion Criteria:
Recipient must meet criteria outlined in the recent Investigational COVID-19 Convalescent
Plasma - Emergency INDs (investigational new drug) guidance
(https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-i…
ion-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds)
Exclusion Criteria:
1. History of prior severe reactions to transfusion of blood products with imputability
of probable or definite as defined by Center of Disease Control National Healthcare
Safety Network Hemovigilance Module [see
https://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf].
2. Has underlying uncompensated and untreatable end stage disease.
3. Fluid overload or other condition that would contraindicate administration of plasma
Houston Methodist Hopsital
Houston, Texas, United States
Eric Salazar, MD, PhD, Principal Investigator
The Methodist Hospital Research Institute